Portzamparc Groupe BNP Paribas advised MaaT Pharma (www.maatpharma.com), a clinical-stage biotechnology company and leader in Microbiome Ecosystem Therapies™ dedicated to improving survival for patients with cancer through immune modulation, on its €9.1 million capital increase.
Portzamparc Groupe BNP Paribas acted as Global Coordinator & Bookrunner of the transaction.
👉 Details of the transaction:
Capital increase of €9.1m at €3.48 per share through a Global Offering composed of:
a private placement of 2,168,072 new ordinary shares for qualified investors for €7.5m,
a public offering to retail investors via PrimaryBid of 447,478 new ordinary shares for €1.6m.
Total of 2,615,550 new ordinary shares issued.
The transaction strengthens MaaT Pharma’s financial position, secures operations beyond upcoming regulatory milestones, and supports the preparation for the potential commercialization of Xervyteg® (MaaT013).
Net proceeds of approximately €8.7m will fund the development of its Microbiome Ecosystem Therapies, the advancement of MaaT033 clinical development, continued discussions with the FDA on a pivotal U.S. study, and general corporate purposes.
Existing shareholders Bpifrance Investissement, Biocodex and Invus Public Entities subscribed for a total of €4.5m (approx. 49% of the Offering).
90-day lock-up commitments from the Company, Bpifrance Investissement and Biocodex.
